- Home
- ACRE vs DRTS Comparison
ACRE vs DRTS Comparison
Compare ACRE & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- DRTS
- Stock Information
- Founded
- ACRE 2011
- DRTS 2015
- Country
- ACRE United States
- DRTS Israel
- Employees
- ACRE 2100
- DRTS N/A
- Industry
- ACRE Real Estate Investment Trusts
- DRTS Medical/Dental Instruments
- Sector
- ACRE Real Estate
- DRTS Health Care
- Exchange
- ACRE Nasdaq
- DRTS Nasdaq
- Market Cap
- ACRE 270.6M
- DRTS 262.6M
- IPO Year
- ACRE 2012
- DRTS N/A
- Fundamental
- Price
- ACRE $4.81
- DRTS $2.92
- Analyst Decision
- ACRE Hold
- DRTS Strong Buy
- Analyst Count
- ACRE 7
- DRTS 2
- Target Price
- ACRE $5.50
- DRTS $8.00
- AVG Volume (30 Days)
- ACRE 420.5K
- DRTS 47.2K
- Earning Date
- ACRE 08-05-2025
- DRTS 08-13-2025
- Dividend Yield
- ACRE 12.50%
- DRTS N/A
- EPS Growth
- ACRE N/A
- DRTS N/A
- EPS
- ACRE N/A
- DRTS N/A
- Revenue
- ACRE $67,129,000.00
- DRTS N/A
- Revenue This Year
- ACRE N/A
- DRTS N/A
- Revenue Next Year
- ACRE N/A
- DRTS N/A
- P/E Ratio
- ACRE N/A
- DRTS N/A
- Revenue Growth
- ACRE 83.51
- DRTS N/A
- 52 Week Low
- ACRE $3.35
- DRTS $1.75
- 52 Week High
- ACRE $7.99
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- ACRE 55.85
- DRTS 47.62
- Support Level
- ACRE $4.76
- DRTS $2.81
- Resistance Level
- ACRE $4.94
- DRTS $3.14
- Average True Range (ATR)
- ACRE 0.12
- DRTS 0.17
- MACD
- ACRE -0.01
- DRTS -0.02
- Stochastic Oscillator
- ACRE 56.90
- DRTS 19.67
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.